JP2012523243A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523243A5
JP2012523243A5 JP2012505149A JP2012505149A JP2012523243A5 JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5 JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5
Authority
JP
Japan
Prior art keywords
promoter
tumor
stem cell
cytotoxic protein
coding region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012505149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523243A (ja
JP5727458B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/054844 external-priority patent/WO2010119039A1/en
Publication of JP2012523243A publication Critical patent/JP2012523243A/ja
Publication of JP2012523243A5 publication Critical patent/JP2012523243A5/ja
Application granted granted Critical
Publication of JP5727458B2 publication Critical patent/JP5727458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012505149A 2009-04-13 2010-04-13 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法 Active JP5727458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16878709P 2009-04-13 2009-04-13
US61/168,787 2009-04-13
PCT/EP2010/054844 WO2010119039A1 (en) 2009-04-13 2010-04-13 Engineered mesenchymal stem cells and method of using same to treat tumors

Publications (3)

Publication Number Publication Date
JP2012523243A JP2012523243A (ja) 2012-10-04
JP2012523243A5 true JP2012523243A5 (cg-RX-API-DMAC7.html) 2013-05-23
JP5727458B2 JP5727458B2 (ja) 2015-06-03

Family

ID=42270435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505149A Active JP5727458B2 (ja) 2009-04-13 2010-04-13 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法

Country Status (12)

Country Link
US (2) US9434925B2 (cg-RX-API-DMAC7.html)
EP (1) EP2419113B1 (cg-RX-API-DMAC7.html)
JP (1) JP5727458B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120088542A (cg-RX-API-DMAC7.html)
CN (1) CN102695517B (cg-RX-API-DMAC7.html)
AU (1) AU2010237130B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1013771A2 (cg-RX-API-DMAC7.html)
CA (1) CA2758120C (cg-RX-API-DMAC7.html)
IL (1) IL215581A0 (cg-RX-API-DMAC7.html)
RU (1) RU2539099C2 (cg-RX-API-DMAC7.html)
SG (1) SG175127A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010119039A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US20130171115A1 (en) * 2011-12-30 2013-07-04 Gang Li Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
CN105950630A (zh) * 2012-02-01 2016-09-21 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
US20130203166A1 (en) * 2012-02-06 2013-08-08 Protobios Llc Stimulation of multipotency of mesenchymal stem cells by chemokine ccl5
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
ES2748662T3 (es) * 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2015100268A1 (en) * 2013-12-23 2015-07-02 The Regents Of The University Of California Mesenchymal stem cells for targeted cancer therapy
CA2936483A1 (en) * 2014-01-17 2015-07-23 Wake Forest University Health Sciences Methods for enhancing the delivery of active agents
CA2956987C (en) * 2014-08-18 2023-03-21 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
CA3003133C (en) * 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
CN104622903B (zh) * 2015-01-20 2018-10-09 奥思达干细胞有限公司 抗恶性黑色素瘤的干细胞制剂及其制备方法
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2016138340A1 (en) * 2015-02-27 2016-09-01 Saint Louis University Tumor suppressor sall1 as a therapeutic agent for treating cancer
EP3262159B1 (en) * 2015-02-27 2019-07-24 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cell expressing klotho
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
WO2017036925A1 (en) * 2015-08-28 2017-03-09 Apceth Gmbh & Co. Kg Mesenchymal stem cells for the treatment of metastatic liver disease
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7260898B2 (ja) 2016-01-15 2023-04-19 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド ガンマデルタｔ細胞の活性化のための方法および組成物
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
EP3426777B1 (en) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
AU2017277499B2 (en) 2016-06-07 2022-07-28 The Pacific Heart, lung & Blood Institute Compositions and methods for treating cancer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS
WO2018009246A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
KR20190109389A (ko) 2016-11-03 2019-09-25 엑소스템 바이오텍 리미티드 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도
KR102737836B1 (ko) 2017-04-03 2024-12-03 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 페닐케톤뇨증을 치료하기 위한 조성물 및 방법
EP4317422A3 (en) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11246890B2 (en) 2018-04-03 2022-02-15 The Board Of Trustees Of The Leland Stanford Junior University Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
JP2021526865A (ja) * 2018-06-14 2021-10-11 ロマ・リンダ・ユニヴァーシティ 急性骨髄性白血病の処置のための操作された造血幹細胞
SG11202103317XA (en) 2018-10-17 2021-05-28 Senti Biosciences Inc Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3876952A4 (en) 2018-11-05 2022-08-24 American Gene Technologies International Inc. VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA
KR20210091740A (ko) 2018-11-06 2021-07-22 카리디 바이오테라퓨틱스, 인크. 세포-매개된 종양용해 바이러스 요법용 향상된 시스템
US20220241337A1 (en) * 2019-02-22 2022-08-04 The Trustees Of Columbia University In The City Of Newyork Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents
SG10201902002SA (en) * 2019-03-06 2020-10-29 Nat Univ Singapore Non-viral modification of mesenchymal stem cells
EP4017512B1 (en) * 2019-08-23 2025-04-02 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
JP2023547728A (ja) 2020-11-06 2023-11-13 アーテック メディカル ジーエムビーエイチ 間葉系幹細胞由来の細胞外小胞およびアルファ－１アンチトリプシンを含むウイルス感染症治療用組成物
EP3995130A1 (en) 2020-11-06 2022-05-11 JunctuCell Biomed Manufacturing GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US7098185B2 (en) * 1998-05-18 2006-08-29 University College London Polypeptide hormone phosphatonin
US20060057553A1 (en) * 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
WO2002069953A1 (en) * 2001-03-01 2002-09-12 The Board Of Regents Of The University Of Texas System Methods of treating lung inflammation
US20030165579A1 (en) * 2002-02-27 2003-09-04 Chih-Hui Lin Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers
EP1544213B1 (en) * 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
JP2006194752A (ja) * 2005-01-14 2006-07-27 Sumitomo Metal Mining Co Ltd Ｘ線回折測定における試料固定方法および試料固定具
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
EP2851422A3 (en) 2007-05-24 2015-06-24 Apceth GmbH & Co. KG CD34neg stem cells for the treatment of gastrointestinal disorders

Similar Documents

Publication Publication Date Title
JP2012523243A5 (cg-RX-API-DMAC7.html)
RU2011146048A (ru) Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
JP2010528008A5 (cg-RX-API-DMAC7.html)
Hacker et al. Towards clinical implementation of adeno-associated virus (AAV) vectors for cancer gene therapy: current status and future perspectives
Marofi et al. Mesenchymal stromal/stem cells: a new era in the cell-based targeted gene therapy of cancer
Power et al. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer
Deng et al. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9
Michelfelder et al. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries
Rahal et al. Oncolytic viral therapy for pancreatic cancer
JP2008056679A5 (cg-RX-API-DMAC7.html)
JP2012010710A5 (cg-RX-API-DMAC7.html)
CA2640528A1 (en) Oncolytic adenoviruses for cancer treatment
AU2015276136A1 (en) Car-expressing NK-92 cells as cell therapeutic agents
Feng et al. Stabilization of G-quadruplex DNA and inhibition of Bcl-2 expression by a pyridostatin analog
JP2016526920A5 (cg-RX-API-DMAC7.html)
Cao et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter
Svyatchenko et al. Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines
Shen et al. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene
Yoon et al. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth
Hemminki From molecular changes to customised therapy
Tang et al. Harnessing Oncolytic Viruses for Targeted Therapy in Triple-Negative Breast Cancer
Gürlevik et al. Meganuclease-mediated virus self-cleavage facilitates tumor-specific virus replication
WO2006125381A1 (en) Tumor targeting gene-virus zd55-il-24, construction method and application thereof
RU2814581C1 (ru) Генетический вектор Ad6/3-hTERT-GMCSF, содержащий геномные последовательности рекомбинантного аденовируса 6 серотипа, промотор теломеразы человека, ген гранулоцитарно-макрофагального колониестимулирующего фактора человека, а также ген белка файбер со встройкой домена fiber knob аденовируса 3 серотипа, обладающий повышенной трансдукцией в опухолевые клетки
Singh Journal of Yeungnam Medical Science